Fundraising FoxGreatPoint Ventures — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Biobot Analytics is a wastewater epidemiology company that measures biomarkers in sewage to assess population health in cities, using technology developed at MIT.
BiotechData & InfrastructureGovTechHealthtechBoston, US
Newsha Ghaeli(President)inMariana Matus(Founder)inMariana Guadalupe Matus Garcia(Executive Officer, Director)Ayo Omojola(Investor)in
BoardVivek Pattipati(Director)in
Board seatAndrew Perlman· per SEC Form D · $13.6M raise · filed Jun 2025
Co-investorsAmerican Family Insurance Institute for Corporate and Social ImpactBlindspot Ventures Management CoDCVC (Data Collective)DesignXDorm RoomHalf Court Ventures+22 more
Hyper provides AI-generated meeting summaries that turn long discussions into concise recaps highlighting key decisions and open questions, including AI transcription of calls.
AI & Machine LearningFuture of WorkSaaS
Co-investorsEniac VenturesVermilion Cliffs VenturesVSC VenturesK5 GlobalRipple VenturesTusk Venture Partners
Inkeep provides a platform for building and deploying AI agents and automations through both code and visual interfaces, serving developers and non-technical users who need to automate customer support, sales, and internal workflows.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSan Francisco, US
Nick Gomez(Founder)inRobert Tran(Founder)inNick G.(Founder)in
Co-investorsCoho DeeptechMyelin VCY CombinatorAndreessen HorowitzKhosla VenturesOwl Rock Capital
Spring Labs provides AI-driven complaint management and resolution handling software for compliance teams.
AI & Machine LearningCrypto & Web3Enterprise SoftwareFintechSaaSLos Angeles, US
Adam Jiwan(Director)Anna Fridman(Founder)John Sun(Founder)inKevin Lewis(Founder)inNathanial Schmitt(Executive Officer)
BoardPeyman Hesami(Director)
Co-investors500 GlobalAlpha Ascent Ventures LlcAugust CapitalBankTech VenturesLobby CapitalMulticoin Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.